MORPHOLOGICAL FEATURES OF TUMORS SUBSTRATE IN MULTIPLE MYELOMA PATIENTS COMPLICATED WITH PLASMACYTOMA

Objective. To study the histological structure of bone marrow (BM) and plasmacytoma tumor substrate in patients with multiple myeloma (MM). Materials and methods. The study included 35 patients (19 men and 16 women) aged 23 to 73 years with newly diagnosed MM. At the first onset of the disease plasmacytoma was diagnosed in 21 patients: bone plasmacytoma, associated with skeletal bones – in 14 patients; extramedullary plasmacytoma, emerging in various organs not connected with bone tissue – in 7 patients. All patients underwent BM trephine biopsy and plasmacytoma biopsy with subsequent histological examination. BM and plasmacytoma histological specimens were studied using LEICA DM4000B microscope. Frequency domain analysis (cross tables, Fisher–Freeman test) was used for data statistical analysis.

Results. The analysis showed that the histological features of BM in MM patients with extramedullary plasmacytoma statistically significantly differed from that in MM patients with bone plasmacytoma and without plasmacytoma. As a result of the analysis, the relationship between BM morphological variant and tumor advancement became apparent. When comparing the morphological pattern of the bone and extramedullary plasmacytomas, no significant differences were found, however, the substrate of the extramedullary plasmacytoma was more often represented by tumor cells with immature morphology as compared to the substrate of the bone plasmacytoma.

Conclusion. The established differences in the histological structure of the BM in MM patients with extramedullary plasmacytoma suggest that this type of the disease stands apart and requires further detailed pathomorphological study.

1. Bartel T.B., Haessler J., Brown T.L. et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009;114(10):2068–76. DOI: 10.1182/blood-2009-03-213280. PMID: 19443657.

2. Bladé J., Fernández de Larrea C., Rosiñol L. et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011;29(28):3805–12. DOI: 10.1200/JCO.2011.34.9290. PMID: 21900099.

3. Bladé J., Kyle R.A., Greipp P.R. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996;93(2):345–51. PMID: 8639427.

4. Varettoni M., Corso A., Pica G. et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010;21(2):325–30. DOI: 10.1093/annonc/mdp329. PMID: 19633044.

5. Varga C., Xie W., Laubach J. et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomidebortezomib combinations. Br J Haematol 2015;169(6):843–50. DOI: 10.1111/bjh.13382. PMID: 26032514.

6. De Larrea C.F., Rosiñol L., Cibeira M.T. et al. Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures. Eur J Haematol 2010;85(5):448–51. DOI: 10.1111/j.1600-0609.2010.01504.x. PMID: 20964719.

7. Rosenblum M.D., Bredeson C.N., Chang C. et al. Subcutaneous plasmacytomas with tropism to sites of previous trauma in a multiple myeloma patient treated with an autologous bone marrow transplant. Am J Hematol 2003;72(4):274–7. DOI: 10.1002/ajh.10296. PMID: 12666140.

8. Rasche L., Bernard C., Topp M.S. et al. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol 2012;91(7):1031–7. DOI: 10.1007/s00277-012-1414-5. PMID: 22286070.

9. Weinstock M., Ghobrial I.M. Extramedullary multiple myeloma. Leuk. Lymphoma 2013; 54(6):1135–41. DOI: 10.3109/10428194.2012.740562. PMID: 23210572.

10. Wu P., Davies F.E., Boyd K. et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma 2009;50(2):230–5. DOI: 10.1080/10428190802657751. PMID: 19197724.

11. Usmani S.Z., Heuck C., Mitchell A. et al. Extramedullary disease portends poor prognosis in multiple myeloma and is overrepresented in high-risk disease even in the era of novel agents. Haematologica 2012;97(11):1761–76. DOI: 10.3324/haematol.2012.065698. PMID: 22689675.

12. Lonial S., Boise L.H., Kaufman J. How I treat high-risk myeloma. Blood 2015;126(13):1536–43. DOI: 10.1182/blood-2015-06-653261. PMID: 26272217.

13. Bladé J., Fernández de Larrea C., Rosiñol L. Extramedullary disease in multiple myeloma in the era of novel agents. Br J Haematol 2015;169(6):763–5. DOI:10.1111/bjh.13384. PMID: 25825255.

14. Cerny J., Fadare O., Hutchinson L. et al. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol 2008;81(1):65–9. DOI:10.1111/j.1600-0609.2008.01087. x. PMID: 18462256.

15. Katodritou E., Gastari V., Verrou E. et al. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res 2009;33(8):1137–40. DOI:10.1016/j.leukres.2009.01.036. PMID: 19250676.

16. Pasmantier M.W., Azar H.A. Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases. Cancer 1969;23(1):167–74. PMID: 5763250.

17. Dawson M.A., Patil S., Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007;92(1):143–4. PMID: 17229655.

18. Firsova M.V., Mendeleeva L.P., Kovrigina A.M. et al. Histopathological Features of Bone Marrow and Extramedullary Sites in Patients with Multiple Myeloma. Blood 2017; 130(Suppl. 1):5358.